Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices

Source of this Article
MarketWatch 3 hours ago 49

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.



BankBit shares this Content always with
Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) CC License

Read Entire Article


Screenshot generated in real time with SneakPeek Suite